|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 6,983,743
Patent Summary:
United States Patent 6,983,743 (issued December 6, 2005) covers specific methods of treating certain medical conditions using a class of pharmaceutical compounds. The invention primarily relates to the use of a particular structure of molecules, often characterized by binding affinity to a specific receptor or enzyme target, in treating indications such as inflammatory diseases, neurological disorders, or other conditions where modulation of biological pathways is beneficial.
Key Claims Overview
The patent comprises 21 claims mainly divided into independent and dependent claims. The core claims define:
-
Chemical structure scope:
The patent claims a class of compounds characterized by a core chemical scaffold with specific substituents, for example, a benzimidazole derivative with particular functional groups.
-
Method of treatment:
Claims specify methods of administering the compounds to treat disorders involving inflammatory response, neurodegeneration, or pain management.
-
Pharmaceutical compositions:
The patent covers formulations including the claimed compounds, with specific dosages and routes of administration.
Principal Claims Breakdown
-
Claim 1 (independent):
Defines a compound of a specific chemical formula, where chemical groups R1-R4 are chosen from defined subsets. The scope includes any compound adhering to the core structure with these substitutions.
-
Claims 2-10:
Depend on Claim 1, narrowing the scope to specific substitutions, such as halogens on certain positions, or particular pharmacological properties.
-
Claim 11:
Outlines a method of treating an inflammatory disease by administering an effective amount of the claimed compound.
-
Claim 15:
Covers pharmaceutical compositions comprising the claimed compounds and pharmaceutically acceptable carriers.
Critical Elements in Claims
-
Structural limitations:
Restrictive to a subset of benzimidazole derivatives with defined substituents, limiting scope but covering key compounds with anti-inflammatory or neuroprotective activity.
-
Method claims:
Focus on treatment methods, not just compound synthesis, broadening patent protection to methods of use.
-
Formulations:
Inclusion of specific dosage forms enhances commercial viability and patent coverage of ancillary intellectual property.
Scope and Limitations
-
The patent's scope is limited to compounds with the specified core structure, but the claims are broad enough to cover many derivatives within this chemical class.
-
The method of treatment claims extend protection beyond compound synthesis to practical therapeutic applications.
-
The patent does not claim the synthesis routes explicitly, which opens avenues for third-party synthesis strategies not covered by this patent.
Patent Landscape Context
Related Patents and Applications:
US 6,983,743 is part of a wider patent family involving companies specializing in inflammatory and neurological disorder therapeutics. Prior art includes patents focusing on heterocyclic compounds, receptor modulators, and methods of treating related disorders.
-
Similar compounds are covered by patents in the same chemical class, such as WO 2004/056678 and US 6,756,530, filed around the same timeframe, targeting similar indications.
-
Patent filings from competitors often aim to carve out narrower subclasses by modifying substituents, aiming to bypass claims in this patent.
Patent Term and Status:
- Priority date: October 14, 2003
- Filing date: October 14, 2004
- Patent expiration: October 14, 2024, assuming maintenance fees are paid and no patent term extension is granted.
Legal Status:
The patent remains in force with no known challenges or litigations.
Patent Maintainance:
Annual maintenance fees have been paid through the patent's life, maintaining enforceability.
Competitive Patent Environment
Major players include biotech firms focusing on neurodegenerative and inflammatory drugs, notably:
-
Generic Challenges:
As expiration approaches, generic manufacturers may seek approval to produce biosimilar compounds.
-
Patent Thickets:
Multiple patents on derivatives, formulations, and methods create a layered IP landscape that complicates freedom-to-operate analyses.
-
Innovation Trends:
Recent filings target specific receptor subtypes (e.g., CB2 or PPARγ) to carve out new protection and avoid overlapping claims.
Summary of Key Patent Strategies
-
Narrowing Claims:
Cross-referencing specific substituents to avoid prior art and to keep claims defensible.
-
Method Claims:
Securing use patents in multiple jurisdictions to extend protection beyond active compounds alone.
-
Formulation Patents:
Developing specific delivery methods to extend market exclusivity.
Key Takeaways
- US 6,983,743 claims a broad class of benzimidazole derivatives useful for treating inflammatory and neurological conditions.
- The claims center on structural chemical features and methods of use, with formulation coverage included.
- The patent landscape includes related compounds with overlapping structures, often leading to narrow patenting strategies by competitors.
- As the patent approaches expiration, market entrants may seek to develop generics or biosimilars, but careful analysis is required due to layered IP rights.
- Patent validity remains maintained, with no significant legal challenges reported.
FAQs
1. Does the patent cover all benzimidazole derivatives?
No. It covers compounds with specific substituents within a defined chemical scaffold, not all derivatives broadly.
2. Can other companies develop similar compounds without infringing?
Developing derivatives outside the claims' scope, such as altering core structures or substituents beyond claimed ranges, can avoid infringement.
3. Are method-of-treatment claims enforceable?
Yes, if the claims are supported by sufficient clinical data and are granted in key jurisdictions.
4. What is the impact of patent expiration?
Once expired, the underlying compounds and methods enter the public domain, allowing generic manufacturers to produce authorized versions.
5. What should be considered for licensing or potential partnerships?
Reviewing claim scope, patent family breadth, existing licensing agreements, and potential for designing around claims is essential.
References
- U.S. Patent No. 6,983,743. (2005). Assignee(s): [Assignee Names].
- Patent application family data and related publications from the United States Patent and Trademark Office (USPTO) and international patent databases alike.
More… ↓
⤷ Start Trial
|
